Navigation Links
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Date:11/24/2008

Company reaffirms its innovation leadership and long-term commitment to hepatitis research

KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today provided a clinical update on boceprevir, its lead investigational oral hepatitis C protease inhibitor currently in Phase III development. The company believes boceprevir has the potential to be a first-in-class and best-in-class protease inhibitor for treating chronic hepatitis C. The company also announced that it is developing a highly potent next-generation oral hepatitis C protease inhibitor that has future best-in-class potential. The compound, known as SCH 900518 is currently in Phase IIa clinical development. The update was presented today as part of the company's 2008 R&D Update meeting at its headquarters in Kenilworth, N.J.

"As pioneers in the hepatitis field, our vision is to apply our experience and innovation, as we have in the past, to continue to redefine and improve treatments for chronic hepatitis C, in the near term and in the future," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute.

The company reported for the first time that in a Phase II study, a 48-week boceprevir regimen achieved an unprecedented 75 percent sustained virologic response (SVR) rate at 24 weeks after the end of treatment (SVR 24) in patients who received 4 weeks of PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) prior to the addition of boceprevir (800 mg TID) (P/R lead-in). This represents a near doubling of the 38 percent SVR 24 rate for patients in the control group receiving 48-weeks of PEGINTRON and REBETOL alone (ITT).(1,2) In a 28-week boceprevir P/R lead-in regimen, the SVR 24 rate was 56 percent. Importantly, for patients who received
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
2. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
3. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
4. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
5. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
6. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
7. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
9. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... WELWYN GARDEN CITY, England and ... Heptares Therapeutics, the leading GPCR drug discovery and development company, ... Akira Usui as a Consultant to augment the Company,s ... Asian territories. Mr Usui has more than 15 years ... pharmaceutical industry including senior roles at Perlegen Sciences, Inc., Roche Pharma ...
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... th Annual  Healthcare Conference on Thursday, May 30, 2013, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
(Date:5/23/2013)... 23, 2013  A recently published clinical study conducted ... Texas , demonstrates that 3D mammography (breast tomosynthesis) ... The study, "Implementation of Breast Tomosynthesis ... led by Stephen L. Rose , ... American Journal of Roentgenology (AJR). The AJR ...
Breaking Medicine Technology:Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3
... ARBOR, Mich., April 7, 2011 Adeona Pharmaceuticals, Inc. (AMEX: ... serious central nervous system diseases, announced today that it has ... its common stock at approximately $2.0725 per share to a ... million in gross proceeds. The investor will also receive warrants ...
... April 7, 2011 Inhibitex, Inc. (Nasdaq: INHX ... of 11,463,415 shares of its common stock, at a purchase ... of $47 million. The net proceeds to Inhibitex from the sale ... offering expenses, are expected to be approximately $44 million.  Inhibitex ...
Cached Medicine Technology:Adeona to Raise $3.5 Million in Registered Direct Offering 2Adeona to Raise $3.5 Million in Registered Direct Offering 3Inhibitex Prices $47 Million Public Offering 2Inhibitex Prices $47 Million Public Offering 3
(Date:5/25/2013)... 2013 The latest report from ... bowel syndrome (IBS) to bloating, constipation, diarrhea and ... long-lasting, embarrassing, frustrating and difficult health issues to ... health have provided a cure for these ... contributing to digestive health issues, a healthy diet ...
(Date:5/25/2013)... According to a new market report,"Global Homeland Security ... is expected to reach $544.02 Billion by 2018 ... studies the major market drivers, restraints, and opportunities ... the World. , Browse:, , ... Figures , 175 Pages and in-depth ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 According to ... most beautiful and powerful women that ever lived. Cleopatra’s ... by some of the most powerful men in her ... beauty remedies to keep her skin glowing and fresh, ... with bees- wax, maringa oil and cyprus grass. , ...
(Date:5/25/2013)... Los Angeles, CA (PRWEB) May 25, 2013 ... will grow at an average annual rate of 28.7% ... growth of 17.9% in 2013. From 2002 and 2008, no ... analyst Kevin Culbert, causing relatively modest growth during that period. ... (FDA) has approved six new products. This factor contributed to ...
(Date:5/25/2013)... DF (PRWEB) May 25, 2013 Ayurveda ... sanscrit: "knowledge or wisdom of life". While a medical science, ... the transformation of consciousness. Its fundamental philosophy is that disease ... our environment. In order to re-establish optimal health, one must ... adopt a life style which brings us back into perfect ...
Breaking Medicine News(10 mins):Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Fundamentos de Ayurveda in Mexico (Ayurvedic Principles) Offered by Escuela de Ayurveda de California 2
... Vladimir Putin ordered his ministry to set up a task ... spread to five regions in southern Russia// . ... Service to be found affecting areas such as Stavropol, Dagestan, ... that he would establish a special structure which would monitor ...
... and Research Institutes, Inc (NDRI) in New York ... explored the role// of social supports, spirituality, religiousness, ... of recovery from addiction. The study reveals markedly ... as a decrease in stress when people were ...
... study conducted by Nancy E. Kemeny, MD, an Attending ... Cancer Center// said that patients whose colorectal cancer ... hepatic arterial infusion (HAI). In this technique chemotherapy was ... the abdomen. It was found that the patients on ...
... don heavily on the Polish recruitment scheme to beef up ... These comments were made even as ministers// welcomed the first ... Fife, Forth Valley and Argyll and Clyde.,The Scottish Executive revealed ... year. The British Dental Association (BDA) has warned that these ...
... 'Potato-potato' burning bright in the hands of you could ... diabetes.,According to a long-term study of nearly 85 000 ... with the highest potato intake had a modestly elevated ... women, who are already at increased risk of the ...
... that women are in a better position in handling stress ... they found that female rodents handle stress better than males,// ... between males and females. ,The three-month research by ... them what is known as the inflammatory response, the body's ...
Cached Medicine News:Health News:Drug Addiction Recovery Buffered by Spirituality 2Health News:Colon cancer patients benefit from Hepatic Arterial Infusion Therapy 2Health News:Men Are Less Capable Of Handling Stress Than Women – New Stud 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: